Business Description
Nurix Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US67080M1036
Share Class Description:
NRIX: Ordinary SharesTotal Employee Number:
357Description
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.63 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.17 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 6.86 | |||||
Beneish M-Score | -4.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.8 | |||||
3-Year EBITDA Growth Rate | 4.7 | |||||
3-Year EPS without NRI Growth Rate | 6.3 | |||||
3-Year FCF Growth Rate | 4.9 | |||||
3-Year Book Growth Rate | -6.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.58 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 33.43 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.26 | |||||
9-Day RSI | 56.16 | |||||
14-Day RSI | 60.24 | |||||
3-1 Month Momentum % | 15.71 | |||||
6-1 Month Momentum % | 3.99 | |||||
12-1 Month Momentum % | 67.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.34 | |||||
Quick Ratio | 6.34 | |||||
Cash Ratio | 6.16 | |||||
Days Sales Outstanding | 188.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.2 | |||||
Shareholder Yield % | -1.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -982.37 | |||||
Net Margin % | -928.44 | |||||
EBITDA Margin % | -935.44 | |||||
FCF Margin % | -828.28 | |||||
OCF Margin % | -798.85 | |||||
ROE % | -76.12 | |||||
ROA % | -57.39 | |||||
ROIC % | -291.33 | |||||
3-Year ROIIC % | 330.7 | |||||
ROC (Joel Greenblatt) % | -503.05 | |||||
ROCE % | -70.4 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 62.34 | |||||
PB Ratio | 6.03 | |||||
Price-to-Tangible-Book | 6.03 | |||||
EV-to-EBIT | -5.65 | |||||
EV-to-EBITDA | -5.93 | |||||
EV-to-Revenue | 55.51 | |||||
EV-to-Forward-Revenue | 43.95 | |||||
EV-to-FCF | -6.7 | |||||
Price-to-GF-Value | 3.74 | |||||
| Price-to-Net-Current-Asset-Value | 7.5 | |||||
| Price-to-Net-Cash | 7.8 | |||||
Earnings Yield (Greenblatt) % | -17.7 | |||||
FCF Yield % | -12.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nurix Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 36.766 | ||
| EPS (TTM) ($) | -3.45 | ||
| Beta | 2.2594 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.41 | ||
| Volatility % | 67.26 | ||
| 14-Day RSI | 60.24 | ||
| 14-Day ATR ($) | 1.23266 | ||
| 20-Day SMA ($) | 23.602 | ||
| 12-1 Month Momentum % | 67.39 | ||
| 52-Week Range ($) | 8.195 - 25.085 | ||
| Shares Outstanding (Mil) | 103.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nurix Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nurix Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-09 | In 76 days | ||
| Second quarter earnings results for 2026 | 2026-07-09 | 24.31 (+2.14%) | ||
| Unlocking the Full Potential of Bexobrutideg | 2026-06-08 08:00 | 14.64 (-4.38%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:05 | 16.37 (-3.82%) | ||
| RBC Global Healthcare Conference | 2026-05-20 13:30 | 15.24 (-0.65%) | ||
| General meeting for 2026 | 2026-05-15 09:00 | 16.00 (-1.11%) | ||
| Needham Virtual Healthcare Conference | 2026-04-13 13:30 | 16.03 (-1.66%) | ||
| First quarter earnings results for 2026 | 2026-04-08 | 16.35 (+4.34%) | ||
| Annual report for 2025 | 2026-01-28 | 19.41 (+3.08%) | ||
| Fourth quarter earnings results for 2025 | 2026-01-28 | 19.41 (+3.08%) |
Show
Entries
Nurix Therapeutics Inc Frequently Asked Questions
What is Nurix Therapeutics Inc(NRIX)'s stock price today?
The current price of NRIX is $23.39. The 52 week high of NRIX is $25.09 and 52 week low is $8.20.
When is next earnings date of Nurix Therapeutics Inc(NRIX)?
The next earnings date of Nurix Therapeutics Inc(NRIX) is 2026-10-09 Est..
Does Nurix Therapeutics Inc(NRIX) pay dividends? If so, how much?
Nurix Therapeutics Inc(NRIX) does not pay dividend.
Guru Commentaries on NAS:NRIX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nurix Therapeutics Inc
Is Nurix Therapeutics Inc (NRIX) Facing Valuation Concerns After Q2 Earnings Miss? GF Score: 50/100, Revenue at $9.0M
Jul 09, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers